The relative net health benefit of liver resection, ablation, and transplantation for early hepatocellular carcinoma

World Journal of Surgery

Volumn 39, Issue 6, 2015, Pages 1474-1484

  Spolverato, Gaya ^a   Vitale, Alessandro ^b   Ejaz, Aslam ^a   Kim, Yuhree ^a   Maithel, Shishir K ^c   Cosgrove, David P ^a   Pawlik, Timothy M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; COMPARATIVE STUDY; COMPLICATION; COST BENEFIT ANALYSIS; ECONOMICS; HOSPITAL ADMISSION; HUMAN; ITALY; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER RESECTION; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MONTE CARLO METHOD; PATHOLOGY; QUALITY ADJUSTED LIFE YEAR; SALVAGE THERAPY; TUMOR RECURRENCE; UNITED STATES;

CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; COST-BENEFIT ANALYSIS; HEPATECTOMY; HUMANS; ITALY; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MONTE CARLO METHOD; NEOPLASM RECURRENCE, LOCAL; QUALITY-ADJUSTED LIFE YEARS; SALVAGE THERAPY; UNITED STATES; WAITING LISTS;

EID: 84937533048     PISSN: 03642313     EISSN: 14322323     Source Type: Journal    
DOI: 10.1007/s00268-015-2987-7     Document Type: Article

References (46)

1. Mazzaferro V, Regalia E, Doci R et al (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334:693-699
2. Bruix J, Sherman M (2011) American Association for the Study of Liver D Management of hepatocellular carcinoma: an update. Hepatology 53:1020-1022
3. Forner A, Hessheimer AJ, Isabel Real M et al (2006) Treatment of hepatocellular carcinoma. Crit Rev Oncol Hematol 60:89-98
4. Nathan H, Bridges JF, Schulick RD et al (2011) Understanding surgical decision making in early hepatocellular carcinoma. J Clin Oncol 29:619-625
5. Adam R, Bhangui P, Vibert E et al (2012) Resection or transplantation for early hepatocellular carcinoma in a cirrhotic liver: does size define the best oncological strategy? Ann Surg 256:883-891
6. Bismuth H, Chiche L, Adam R et al (1993) Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg 218:145-151
7. Cherqui D, Laurent A, Mocellin N et al (2009) Liver resection for transplantable hepatocellular carcinoma: long-term survival and role of secondary liver transplantation. Ann Surg 250:738-746
8. Park YK, Kim BW, Wang HJ et al (2009) Hepatic resection for hepatocellular carcinoma meeting Milan criteria in Child-Turcotte-Pugh class a patients with cirrhosis. Transpl Proc 41:1691-1697
9. Cunningham SC, Tsai S, Marques HP et al (2009) Management of early hepatocellular carcinoma in patients with well-compensated cirrhosis. Ann Surg Oncol 16:1820-1831
10. Ni JY, Xu LF, Sun HL et al (2013) Percutaneous ablation therapy versus surgical resection in the treatment for early-stage hepatocellular carcinoma: a meta-analysis of 21,494 patients. J Cancer Res Clin Oncol 139:2021-2033
11. Cucchetti A, Piscaglia F, Cescon M et al (2013) Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma. J Hepatol 59:300-307
12. Lim KC, Wang VW, Siddiqui FJ, et al.(2014) Cost-effectiveness analysis of liver resection versus transplantation for early hepatocellular carcinoma within the Milan criteria. Hepatology. doi: 10.1002/hep.27135
13. Stinnett AA (1998) Mullahy J Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making 18:S68-S80
14. Grosse SD (2008) Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res 8:165-178
15. Lang K, Danchenko N, Gondek K et al (2009) The burden of illness associated with hepatocellular carcinoma in the United States. J Hepatol 50:89-99
16. Mazzaferro V, Llovet JM, Miceli R et al (2009) Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 10:35-43
17. Onaca N, Davis GL, Goldstein RM et al (2007) Expanded criteria for liver transplantation in patients with hepatocellular carcinoma: a report from the International Registry of Hepatic Tumors in Liver Transplantation. Liver Transpl 13:391-399
18. Volk ML, Vijan S, Marrero JA (2008) A novel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan criteria American journal of transplantation. J Am Soc Transpl Am Soc Transpl Surg 8:839-846
19. Beck JR, Kassirer JP, Pauker SG (1982) A convenient approximation of life expectancy (the "DEALE"). I. Validation of the method. Am J Med 73:883-888
20. Salvalaggio PR, Dzebisashvili N, MacLeod KE et al (2011) The interaction among donor characteristics, severity of liver disease, and the cost of liver transplantation. Liver Transpl 17:233-242
21. Trotter JF, Mackenzie S, Wachs M et al (2003) Comprehensive cost comparison of adult-adult right hepatic lobe living-donor liver transplantation with cadaveric transplantation. Transplantation 75:473-476
22. Sagmeister M, Mullhaupt B, Kadry Z et al (2002) Cost-effectiveness of cadaveric and living-donor liver transplantation. Transplantation 73:616-622
23. Sagmeister M, Renner EL, Mullhaupt B et al (2002) Simulation of hepatitis C based on a mandatory reporting system. Eur J Gastroenterol Hepatol 14:25-34
24. Majno PE, Sarasin FP, Mentha G et al (2000) Primary liver resection and salvage transplantation or primary liver transplantation in patients with single, small hepatocellular carcinoma and preserved liver function: an outcome-oriented decision analysis. Hepatology 31:899-906
25. Fuks D, Dokmak S, Paradis V et al (2012) Benefit of initial resection of hepatocellular carcinoma followed by transplantation in case of recurrence: an intention-to-treat analysis. Hepatology 55:132-140
26. N'Kontchou G, Aout M, Laurent A et al (2012) Survival after radiofrequency ablation and salvage transplantation in patients with hepatocellular carcinoma and Child-Pugh A cirrhosis. J Hepatol 56:160-166
27. Vitale A, Volk ML, Pastorelli D et al (2010) Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety. Hepatology 51:165-173
28. Erlinge D, Gotberg M, Lang I et al (2014) Rapid endovascular catheter core cooling combined with cold saline as an adjunct to percutaneous coronary intervention for the treatment of acute myocardial infarction. The CHILL-MI trial: a randomized controlled study of the use of central venous catheter core cooling combined with cold saline as an adjunct to percutaneous coronary intervention for the treatment of acute myocardial infarction. J Am Coll Cardiol 63:1857-1865
29. Fenwick E, O'Brien BJ, Briggs A (2004) Cost-effectiveness acceptability curves-facts, fallacies and frequently asked questions. Health Econ 13:405-415
30. Siegel JE, Weinstein MC, Russell LB et al (1996) Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA 276:1339-1341
31. Cucchetti A, Piscaglia F, Cescon M et al (2013) Systematic review of surgical resection vs radiofrequency ablation for hepatocellular carcinoma. World J Gastroenterol 19:4106-4118
32. Nathan H, Segev DL, Mayo SC et al (2012) National trends in surgical procedures for hepatocellular carcinoma: 1998-2008. Cancer 118:1838-1844
33. Washburn K, Edwards E, Harper A et al (2010) Hepatocellular carcinoma patients are advantaged in the current liver transplant allocation system. Am J Transpl 10:1643-1648
34. Landman MP, Feurer ID, Pinson CW et al (2011) Which is more cost-effective under the MELD system: primary liver transplantation, or salvage transplantation after hepatic resection or after loco-regional therapy for hepatocellular carcinoma within Milan criteria? HPB 13:783-791
35. Zimmerman MA, Ghobrial RM, Tong MJ et al (2008) Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators Archives of surgery 143:182-188 discussion 188
36. Cha CH, Ruo L, Fong Y et al (2003) Resection of hepatocellular carcinoma in patients otherwise eligible for transplantation. Ann Surg 238:315-321 discussion 321-313
37. Xu XS, Liu C, Qu K et al (2014) Liver transplantation versus liver resection for hepatocellular carcinoma: a meta-analysis. Hepatobiliary Pancreat Dis Int 13:234-241
38. Izumi R, Shimizu K, Ii T et al (1994) Prognostic factors of hepatocellular carcinoma in patients undergoing hepatic resection. Gastroenterology 106:720-727
39. Cucchetti A, Vitale A, Del Gaudio M et al (2010) Harm and benefits of primary liver resection and salvage transplantation for hepatocellular carcinoma. Am J Transpl 10:619-627
40. Buscarini L, Buscarini E, Di Stasi M et al (2001) Percutaneous radiofrequency ablation of small hepatocellular carcinoma: long-term results. Eur Radiol 11:914-921
41. Lencioni R, Cioni D, Crocetti L et al (2005) Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology 234:961-967
42. Chou CT, Chou JM, Chang TA et al (2013) Differentiation between dysplastic nodule and early-stage hepatocellular carcinoma: the utility of conventional MR imaging. World J Gastroenterol 19:7433-7439
43. Poon RT, Fan ST, Lo CM et al (2002) Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg 235:373-382
44. Chan AC, Chan SC, Chok KS et al (2013) Treatment strategy for recurrent hepatocellular carcinoma: salvage transplantation, repeated resection, or radiofrequency ablation? Liver transpl 19:411-419
45. Polesel J, Zucchetto A, Montella M et al (2009) The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma. Ann Oncol 20:353-357
46. Naugler WE, Sonnenberg A (2010) Sonnenberg a survival and cost-effectiveness analysis of competing strategies in the management of small hepatocellular carcinoma. Liver Transpl 16:1186-1194